
Fermenta Biotech Q4 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- The company expects about a 20%-25% increase in volumes from capacity expansions, particularly if fully utilized for Vitamin D3, which can significantly boost revenue.
- New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next two quarters, which could further drive growth.
- The Saykha plant’s implementation is delayed but will provide additional capacity for new products and minerals, supporting future volume growth.
- The human nutrition segment has grown steadily, with a focus on expanding market share, indicating potential revenue increases in this segment.
- Animal feed volumes and prices have been volatile and suppressed; a recovery could lead to improved margins and higher revenues, but this remains uncertain.
- The management refrains from giving specific volume guidance due to market volatility but remains confident in achieving an average EBITDA margin of around 20% over 4-5 years, reflecting steady operational growth.
See what Fermenta Biotech management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company is being cautious about over-leveraging and does not plan to significantly increase debt for upcoming CAPEX requirements, particularly for the Saykha project.
- For certain new products like pre-mixes, the company has already taken additional debt, increasing it by about Rs. 25 to 30 crores for the Kullu project.
- No anticipated CAPEX-related debt is expected for new products like Vitamin K1 and vegan D3 as they will utilize existing multi-purpose plants.
- The company is monetizing land assets (e.g., Thane, Pune) to fund investments, aiming to avoid increasing debt levels.
- No specific mention of equity fundraising was indicated in the transcript.
See what Fermenta Biotech management said on order book — free account, 30 seconds.
Capex plans
Yes- Saykha Project: Estimated total investment of Rs. 150 to Rs. 200 crores to be done in phases; currently delayed due to resource availability and strategic decisions (Page 13).
- Pre-mix Plant: Initiated as a brownfield project in Kullu; plant expected to be commissioned and commercialized by Q4 FY22 (Page 8 and 13).
- Multi-purpose Plant Expansion at Dahej: Capacity expansion completed; supports Vitamin D3 and upcoming products like K1 and vegan D3 without additional CAPEX for these products (Page 10 and 14).
- Cautious approach on new CAPEX to avoid over-leveraging; preference to monetize land assets (Page 12, 13).
- Thane Land: Developing through joint venture Mextech Properties, monetizing via development rights without upfront capital expenditure (Page 12).
- No anticipated CAPEX for new products like K1 and vegan D3 initially, leveraging existing Dahej plant capacity (Page 13).
- Debt increased by Rs. 25-30 crores for Kullu pre-mix plant; no significant additional debt planned currently (Page 12).
Track Fermenta Biotech — get its next earnings analysis in your feed
How does Fermenta Biotech rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Fermenta Biotech rank in Pharmaceuticals & Biotechnology?
Compare Fermenta Biotech against every Pharmaceuticals & Biotechnology company (Q4 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem